Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Leukemia patients to be given varicella vaccine

Leukemia patients to be given varicella vaccine Varicella vaccine, still experimental in this country, is being used in an effort to protect leukemia patients from potentially fatal chickenpox. The project eventually will involve 500 patients with acute lymphocytic leukemia who never have had chickenpox and lack antibodies to the varicella-zoster virus. An additional group of leukemia patients— those who have survived natural varicella infection without vaccination—are being recruited as controls. The National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Md, which is supporting the study, estimates that up to 7% of immunosuppressed leukemia patients who contract varicella will die. That estimate is largely based on treatment of 77 young cancer patients at St. Jude's Children's Research Hospital, Memphis. Sixty of these patients were immunosuppressed when they developed varicella; four died (Pediatrics 1975;56:388-397). Among presumably healthy persons, the varicella death-to-case ratio recently in this country has been 6.7/10,000, according to data compiled by Stephen R. Preblud, MD, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Leukemia patients to be given varicella vaccine

Gunby, Phil
JAMA , Volume 247 (17) – May 7, 1982
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/leukemia-patients-to-be-given-varicella-vaccine-h108jXo3e5

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright © 1982 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1982.03320420012007
Publisher site
See Article on Publisher Site

Abstract

Varicella vaccine, still experimental in this country, is being used in an effort to protect leukemia patients from potentially fatal chickenpox. The project eventually will involve 500 patients with acute lymphocytic leukemia who never have had chickenpox and lack antibodies to the varicella-zoster virus. An additional group of leukemia patients— those who have survived natural varicella infection without vaccination—are being recruited as controls. The National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Md, which is supporting the study, estimates that up to 7% of immunosuppressed leukemia patients who contract varicella will die. That estimate is largely based on treatment of 77 young cancer patients at St. Jude's Children's Research Hospital, Memphis. Sixty of these patients were immunosuppressed when they developed varicella; four died (Pediatrics 1975;56:388-397). Among presumably healthy persons, the varicella death-to-case ratio recently in this country has been 6.7/10,000, according to data compiled by Stephen R. Preblud, MD,

Journal

JAMA – American Medical Association

Published: May 7, 1982

There are no references for this article.